Portage Biotech Files January 2025 6-K Report
Ticker: ATON · Form: 6-K · Filed: Jan 30, 2025 · CIK: 1095435
| Field | Detail |
|---|---|
| Company | Portage Biotech INC. (ATON) |
| Form Type | 6-K |
| Filed Date | Jan 30, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $2,150,000, $4, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, routine-report
TL;DR
Portage Biotech filed its monthly 6-K, standard procedure, no major news.
AI Summary
Portage Biotech Inc. filed a Form 6-K on January 30, 2025, reporting for the month of January 2025. The company is incorporated in the British Virgin Islands and its principal executive office is located in Tortola. This filing is incorporated by reference into its S-8 registration statement (File No. 333-275842).
Why It Matters
This filing provides routine updates and incorporates information into existing registration statements, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine filing that does not contain new material financial information or significant operational updates.
Key Players & Entities
- PORTAGE BIOTECH INC. (company) — Filer of the report
- 001-40086 (company) — SEC File Number
- 333-275842 (company) — Form S-8 File Number
- January 2025 (date) — Reporting period
- January 30, 2025 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically used to furnish information that the issuer makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.
What is the reporting period for this Form 6-K?
This Form 6-K is for the month of January 2025.
What is Portage Biotech Inc.'s principal executive office address?
The principal executive office is located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110.
Is Portage Biotech Inc. required to file annual reports under Form 20-F or Form 40-F?
Portage Biotech Inc. indicates it files annual reports under cover of Form 20-F.
How is this filing incorporated by reference?
This report on Form 6-K is incorporated by reference into the registration statement on Form S-8 (File No. 333-275842) of Portage Biotech Inc.
Filing Stats: 471 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-01-30 16:46:00
Key Financial Figures
- $2,150,000 — nary shares for aggregate proceeds of US$2,150,000, at a per share price of US$4.10, the c
- $4 — US$2,150,000, at a per share price of US$4.10, the closing price of a share on the
- $500,000 — the shares being registered is at least $500,000. The registration rights agreement has
Filing Documents
- f6k_012925.htm (6-K) — 12KB
- exh_41.htm (EX-4.1) — 39KB
- exh_42.htm (EX-4.2) — 150KB
- exh_991.htm (EX-99.1) — 5KB
- 0001171843-25-000535.txt ( ) — 207KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-40086 PORTAGE BIOTECH INC. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] INCORPORATION BY REFERENCE This report on Form 6-K (including any exhibits attached hereto) shall be deemed to be incorporated by reference into the registration statement on Form S-8 (File No. 333-275842) of Portage Biotech Inc. (including any prospectuses forming a part of such registration statement) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Entry into Material Agreements – Sale of Ordinary Shares On January 29, 2025, Portage Biotech Inc. (the “Company”) completed the sale of 524,390 ordinary shares for aggregate proceeds of US$2,150,000, at a per share price of US$4.10, the closing price of a share on the Nasdaq Stock Market on the date preceding the date of the securities purchase agreement. The shares were sold to two directors of the Company, Messrs. Gregory Bailey and James Mellon. The shares were sold in a private placement transaction pursuant to Regulation S, and are being issued as restricted stock. The proceeds will be used for general corporate purposes and working capital. In connection with the sale of the shares, the Company entered into a registration rights agreement that provides for two demand registrations at any time on a Form F-1 or equivalent and once each year on a Form F-3, provided the anticipated value of the shares being registered is at least $500,000. The registration rights agreement has a term of seven years. The Company is obligated to pay the costs of the registration statement but not any broker or other selling commissions due to a broker or dealer engaged by the selling shareholders. The forms of securities purchase agreement and registration rights agreement and a copy of the press release is filed herewith as exhibits. Exhibits Exhibit Number Description 4.1 Form of Securities Purchase Agreement to purchase ordinary shares, dated January 23, 2025. 4.2 Registration Rights Agreement dated January 23, 2025. 99.1 Press Release dated January 30, 2025. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: January 30, 2025 PORTAGE BIOTECH INC. By: /s/ Andrea Park Andrea Park Chief Financial Officer